Sutherland I A, Leathwick D M, Brown A E, Miller C M
AgResearch, Grasslands, Palmerston North, New Zealand.
Vet Rec. 1997 Aug 2;141(5):120-3. doi: 10.1136/vr.141.5.120.
Three groups of newly-weaned Romney lambs were given either a standard oral dose of albendazole, a controlled-release capsule containing albendazole, or a standard oral dose of moxidectin. At 10, 20, 30 and 40 days after treatment, sub-groups of lambs were given 10,000 infective-stage larvae of either a drug-resistant or a drug-susceptible strain of Ostertagia circumcincta. The recommended oral dose of albendazole removed 32 per cent of the resistant strain and over 99.9 per cent of the susceptible O. circumcincta. The recommended oral dose of moxidectin removed 91 per cent of the resistant strain and over 99.9 per cent of the susceptible parasites. None of the lambs treated with controlled-release capsules was challenged at 20 or 30 days after treatment. Twenty-one days after challenge, samples of faeces were taken to determine the presence of nematode eggs and cultured to establish the proportion of eggs developing to infective-stage larvae (L3). Abomasa were recovered after slaughter and worm burdens determined. In the lambs given controlled-release capsules only the resistant parasites were able to establish, and there were significantly fewer than in the lambs treated orally with albendazole. The proportion of the eggs from resistant parasites which developed to L3 was not reduced by the presence of the capsules. Oral moxidectin provided no protection against the establishment of the resistant strain and viable L3 were recovered after challenge with resistant parasites 10 days after treatment; however, the establishment of susceptible O. circumcincta was reduced by more than 99 per cent. The establishment of the susceptible parasites in the lambs treated with moxidectin increased with time and was not significantly lower than in the other groups by 30 days after treatment.
将三组刚断奶的罗姆尼羔羊分别给予标准口服剂量的阿苯达唑、含阿苯达唑的控释胶囊或标准口服剂量的莫西菌素。在治疗后10、20、30和40天,给羔羊亚组分别接种10000条感染阶段的环形泰勒虫耐药株或敏感株幼虫。推荐口服剂量的阿苯达唑清除了32%的耐药株和超过99.9%的敏感环形泰勒虫。推荐口服剂量的莫西菌素清除了91%的耐药株和超过99.9%的敏感寄生虫。用控释胶囊治疗的羔羊在治疗后20天或30天均未受到攻击。攻击后21天,采集粪便样本以确定线虫卵的存在,并进行培养以确定发育为感染阶段幼虫(L3)的卵的比例。屠宰后回收皱胃并确定虫负荷。在仅给予控释胶囊的羔羊中,只有耐药寄生虫能够定殖,且数量明显少于口服阿苯达唑治疗的羔羊。胶囊的存在并未降低耐药寄生虫发育为L3的卵的比例。口服莫西菌素对耐药株的定殖没有保护作用,在治疗后10天用耐药寄生虫攻击后回收了活的L3;然而,敏感环形泰勒虫的定殖减少了99%以上。用莫西菌素治疗的羔羊中敏感寄生虫的定殖随时间增加,在治疗后30天时并不显著低于其他组。